EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC 4.0

Effects of Aliskiren Monotherapy on Chronic Kidney Disease: A Systematic Review and Meta‐Analysis of Blood Pressure and Urinary Protein Excretion Outcomes

N M Mahmudul Alam Bhuiya, Joshua Caballero, Henry N Young, Lorenzo Villa-Zapata

The Journal of Clinical Hypertension · 2026-03 · 28 (3)

DOI: 10.1111/jch.70237 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift The Journal of Clinical Hypertension, online erschienen am 21.03.2026. Verfasst von N M Mahmudul Alam Bhuiya und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Administrative Pharmacy, College of Pharmacy, University of Georgia, Athens, Georgia, USA. Hauptthemen laut MEDLINE: Fumarates, Amides, Antihypertensive Agents, Renal Insufficiency, Chronic. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aliskiren has been proposed as an alternative for renin‐angiotensin system blockage in chronic kidney disease (CKD); however, its efficacy and safety remain uncertain. The objective of this study was to evaluate the antihypertensive and antiproteinuric effects of aliskiren monotherapy in patients with CKD and hypertension. PRISMA 2020 guidelines were adopted for this systematic review and meta‐analysis (PROSPERO: CRD420251024983). Relevant studies published (January 2001–February 2026) were identified in PubMed and Web of Science that compared aliskiren monotherapy with placebo or other antihypertensives in adults with CKD. Random‐effects models were used to assess changes in systolic blood pressure (SBP), diastolic blood pressure (DBP), and urinary protein excretion. Risk of bias was evaluated using the RoB 2 and ROBINS‐I tools. Nine trials (eight for quantitative analysis) were included. Overall, aliskiren did not significantly reduce SBP (MD −2.91 mmHg; 95% CI −8.74 to 2.91; p = 0.33) or DBP ( n = 300; MD −1.35 mmHg; 95% CI −4.72 to 2.02; p = 0.43). In subgroup analysis, short‐term trials (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FumaratesAmidesAntihypertensive AgentsRenal Insufficiency, ChronicHypertensionProteinuriaHumansBlood PressureTreatment OutcomeRenin-Angiotensin System

Stichwörter der Autor:innen

CKDDRIalbuminuriaaliskirenhypertensionmeta‐analysis

Substanzen

aliskirenFumaratesAmidesAntihypertensive Agents

Autor:innen und Institutionen

  • Department of Clinical and Administrative Pharmacy, College of Pharmacy, University of Georgia, Athens, Georgia, USA.

Zitieren

APA

Bhuiya, N. M. M. A., Caballero, J., Young, H. N., & Villa-Zapata, L. (2026). Effects of Aliskiren Monotherapy on Chronic Kidney Disease: A Systematic Review and Meta‐Analysis of Blood Pressure and Urinary Protein Excretion Outcomes. The Journal of Clinical Hypertension, 28(3). https://doi.org/10.1111/jch.70237

Vancouver

Bhuiya NMMA, Caballero J, Young HN, Villa-Zapata L. Effects of Aliskiren Monotherapy on Chronic Kidney Disease: A Systematic Review and Meta‐Analysis of Blood Pressure and Urinary Protein Excretion Outcomes. The Journal of Clinical Hypertension. 2026;28(3). doi:10.1111/jch.70237

BibTeX
@article{Bhuiya2026,
  author = {Bhuiya, N M Mahmudul Alam and Caballero, Joshua and Young, Henry N and Villa-Zapata, Lorenzo},
  title = {Effects of Aliskiren Monotherapy on Chronic Kidney Disease: A Systematic Review and Meta‐Analysis of Blood Pressure and Urinary Protein Excretion Outcomes},
  journal = {The Journal of Clinical Hypertension},
  year = {2026},
  volume = {28},
  number = {3},
  doi = {10.1111/jch.70237}
}
Kostenlos starten →